Cover Image
市場調查報告書

PharmaPoint:乾眼症症候群 - 全球醫藥品的預測與市場分析

PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024

出版商 GlobalData 商品編碼 296449
出版日期 內容資訊 英文 283 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:乾眼症症候群 - 全球醫藥品的預測與市場分析 PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024
出版日期: 2015年11月05日 內容資訊: 英文 283 Pages
簡介

本報告提供全球的乾眼症症候群市場現況與未來展望相關分析,提供疾病概要和今後流行病學的預測(今後11年份),主要國家的預防體系,再加上主要企業簡介與代表性產品,市場未滿足需求與未來性的機會,目前臨床實驗中的開發中產品資訊,今後的市場規模及影響要素等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理
    • 病因
    • 病理生理學
    • 預測
    • 分類
    • 生活品質(QoL)
  • 症狀

第4章 流行病學

  • 風險要素和合併症
    • 40歲以後,每10年乾眼症症候群的風險便逐步上升35%
    • 女性比男性罹患率高2倍
    • 使用特定的醫藥品,有可能提升乾眼症風險
    • 食用含多量ω-3脂肪酸的食物,關係到乾眼症症候群的預防
    • 特定的環境要素會讓乾眼症風險倍增
  • 全世界的趨勢
    • 美國
    • 歐洲主要5個國家
    • 亞洲
  • 預測手法
    • 利用之資訊來源
    • 預測的前提條件與手法
    • 未利用之資訊來源
  • 流行病學的預測(今後11年份)
    • 乾眼症症候群的發病數量
    • 各年齡的發病數量
    • 男女的發病數量
    • 年齡標準化的發病數量
  • 議論
    • 流行病學趨勢的結論
    • 分析的限制
    • 分析的優勢

第5章 疾病的管理

  • 概要
    • 疾病概要
    • 治療的指南
    • 治療概要
  • 美國
    • 診斷
    • 臨床診療
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 中國
  • 印度

第6章 競爭環境

  • 概要
  • 競爭企業的策略性評估
  • 產品簡介:領導品牌
    • 眼用乳劑Restasis(Cyclosporine0.05%)
    • Diquas(diquafosol tetrasodium)
    • 眼用乳劑Mucosta(rebamipide2%)
    • 額外的治療方法

第7章 市場機會及未滿足需求

  • 概要
  • 診斷檢驗,未能充分鎖定出患者的次級族群
  • 頻繁的給藥和副作用,成了按時服藥的限制
  • 醫生不足和患者的認知度低
  • 臨床實驗的設計,是通過認證的醫藥品太少的原因
  • 未滿足需求的差距分析
  • 為評估乾眼症徵兆和嚴重性的綜合性方式
  • 提升中度患者的治療率

第8章 開發平台評估

  • 概要
  • 臨床實驗設計(各國,各階段·各臨床實驗階段)
  • 臨床實驗中有前途的疫苗
    • Lifitegrast
    • CF-101
    • Cyclokat
    • EGP-437
    • RX-10045
    • MIM-D3

第9章 現在·未來市場參與企業

  • 概要
  • 企業策略概要
  • 企業簡介
    • Allergan
    • Alcon(Novartis AG的完全子公司)
    • Santen Pharmaceutical
    • Shire/SARcode Bioscience
    • 大塚集團
    • Can-Fite Biopharma
    • Eyegate Pharma

第10章 市場預測

  • 全球市場
    • 市場預測
    • 市場促進·阻礙因素:全球性課題
  • 美國
    • 市場預測
    • 近幾年主要的事項
    • 市場促進·阻礙因素
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 中國
  • 印度

第11章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC121PIDR

Dry Eye Syndrome (DES), also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface. This ocular condition can cause ocular discomfort, visual disturbances, and tear film instability, which can potentially damage the ocular surface. The DES market has had few new therapeutics in the last decade with Japan seeing the most change in this time with the arrival of Diquas and Mucosta in 2010 and 2013, respectively. However, the lack of treatment options is about to change with the expected launch of numerous pipeline DES drugs during the forecast period, which will be a significant driver of growth in the 9MM. Indeed, this change has already been initiated with Ikervis' recent arrival in Europe in 2015. Furthermore, additional marketing approvals are being sought for currently marketed DES drugs, Restasis and Diquas, in new countries in the 9MM, which will provide a source of growth in this market.

Highlights

Key Questions Answered

  • The DES market has been dominated by artificial tears therapy and by Restasis (in the US) for many years, with little approved therapeutic options available in the 9MM. New classes of drugs are anticipated the reach the market within the forecast period. How will these change the market overall during the forecast period? Will Restasis maintain market dominance in 2024?
  • The current late stage DES pipeline is varied, with first-in-class drugs in development with innovative modes of action. Which of these will have the biggest impact on the market? What strategies are developers undertaking to penetrate this chronically underserved market? Will these fulfil any unmet needs?
  • Population aging is occurring in almost all countries worldwide, particularly in the 9MM. This is expected to have a significant impact on the prevalence of age-related diseases such as DES. How will epidemiological changes impact the growth of the future market?

Key Benefits

  • The main driver of growth in the DES market will be the introduction of first-in-class drugs over the forecast period. The launch of these therapies will act as a stimulant for growth in this chronically underserved market.
  • DES has been a high risk indication for developers, with numerous drugs failing in late stage development. This has acted as a significant barrier to growth in this market historically.
  • The arrival of new therapies across the 9MM will increase treatment rates and provide alternative options for many patients.
  • The largest unmet need in the DES market will remain the lack of additional safe and efficacious therapeutics with novel modes of action. In addition, simplifying dosing regimens is an important consideration for companies developing drugs to treat these patients.

Scope

  • Overview of DES, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized DES market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
  • Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the glaucoma therapeutics market.
  • Pipeline analysis: focus on the four late-stage pipeline DES drugs discussing emerging trends as well as overview of earlier phase drugs.
  • Analysis of the current and future market competition in the global DES therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global glaucoma therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global DES therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global DES therapeutics market from 2014-2024.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Disease Classification
  • 3.3. Symptoms
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Epidemiology

  • 4.1. Risk Factors and Comorbidities
    • 4.1.1. Risk of Dry Eye Syndrome Increases 35% Each Decade after Age 40
    • 4.1.2. Women are twice as likely to have Dry Eye Syndrome as men
    • 4.1.3. Use of certain medications may increase the risk of developing Dry Eye Syndrome
    • 4.1.4. Diets rich in Omega-3 fatty acid may prevent dry eye syndrome
    • 4.1.5. Certain environmental conditions can double the risk of Dry Eye Syndrome
  • 4.2. Global Trends
    • 4.2.1. US
    • 4.2.2. 5EU
    • 4.2.3. Asia
  • 4.3. Forecast Methodology
    • 4.3.1. Sources used
    • 4.3.2. Forecast Assumptions and Methods -Total Prevalent Cases of Dry Eye Syndrome
    • 4.3.3. Sources Not Used
  • 4.4. Epidemiology Forecast for Dry Eye Syndrome (2014-2024)
    • 4.4.1. Total Prevalent Cases of Dry Eye Syndrome
    • 4.4.2. Age-Specific Total Prevalent Cases
    • 4.4.3. Sex-Specific Total Prevalent Cases
    • 4.4.4. Age-Standardized Total Prevalence of Dry Eye Syndrome
    • 4.4.5. Total Prevalent Cases of Dry Eye Syndrome by Severity
  • 4.5. Discussion
    • 4.5.1. Conclusions on Epidemiology Trends
    • 4.5.2. Limitations of Analysis
    • 4.5.3. Strengths of Analysis

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Diagnosis
    • 5.1.2. Treatment Guidelines
    • 5.1.3. Clinical Practice
  • 5.2. US
  • 5.3. 5EU
  • 5.4. Japan
  • 5.5. China
  • 5.6. India

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Product Profiles
    • 6.2.1. Restasis (cyclosporine)
    • 6.2.2. Diquas (diquafosol tetrasodium)
    • 6.2.3. Mucosta ophthalmic solution (rebamipide)
    • 6.2.4. Ikervis (cyclosporine)
    • 6.2.5. Artificial Tears
    • 6.2.6. Other therapies

7. Unmet Need and Opportunity

  • 7.1. Overview
  • 7.2. New Therapies for DES
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Better Diagnostic Tools
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Appropriate Clinical Trial Design to Secure Regulatory Approval
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Simplified Dosing
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity
  • 7.6. Patient Education to Improve Tolerance and Compliance
    • 7.6.1. Unmet Need
    • 7.6.2. Gap Analysis
    • 7.6.3. Opportunity
  • 7.7. Improved Physician and Patient Disease Awareness
    • 7.7.1. Unmet Need
    • 7.7.2. Gap Analysis
    • 7.7.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trial Design for DES
    • 8.2.2. Ora for DES Drug Development
  • 8.3. Promising Drugs in Clinical Development
    • 8.3.1. Lifitegrast
    • 8.3.2. Tavilermide
    • 8.3.3. Visomitin
    • 8.3.4. RGN-259
    • 8.3.5. Cis-UCA
    • 8.3.6. SI-614
  • 8.4. Promising Drugs in Early-Stage Development
    • 8.4.1. KPI-121
    • 8.4.2. Ozagrel
    • 8.4.3. P-321
    • 8.4.4. Dextenza (OTX-DP)
  • 8.5. Other Drugs in Development

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Alcon
    • 9.3.2. Allergan
    • 9.3.3. Herantis
    • 9.3.4. Mimetogen
    • 9.3.5. Mitotech
    • 9.3.6. Otsuka
    • 9.3.7. RegeneRx
    • 9.3.8. Santen
    • 9.3.9. Shire

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. US
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. 5EU
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Japan
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. China
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. India
    • 10.6.1. Forecast
    • 10.6.2. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed DES Patients
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Launch Dates
    • 11.4.4. General Pricing Assumptions
    • 11.4.5. Individual Drug Assumptions
    • 11.4.6. Pricing of Pipeline Agents
  • 11.5. Primary Research - KOLs Interviewed for this Report
  • 11.6. Primary Research - High-prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Analyst
    • 11.7.2. Therapy Area Director
    • 11.7.3. Epidemiologist
    • 11.7.4. Global Head of Healthcare
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Symptoms of Dry Eye Syndrome
  • Table 2: Risk Factors and Comorbidities for Dry Eye Syndrome
  • Table 3: Sources of Epidemiology Data Used for the Forecast of Total Prevalent Cases of Dry Eye Syndrome in the 9MM
  • Table 4: 9MM, Total Prevalent Cases of Dry Eye Syndrome, Ages ≥20 Years, Men and Women, N, Selected Years 2014-2024
  • Table 5: 9MM, Total Prevalent Cases of Dry Eye Syndrome, by Age Group, Men and Women, N (Row %), 2014
  • Table 6: 9MM, Total Prevalent Cases of Dry Eye Syndrome, by Sex, Ages ≥20 Years, N, (Row %), 2014
  • Table 7: 9MM, Prevalent Cases of Dry Eye Syndrome, by Severity, Ages ≥45 Years, N (Millions) (Row %), 2014
  • Table 8: National and International Treatment Guidelines for DES
  • Table 9: Country Profile - US
  • Table 10: Country Profile - 5EU
  • Table 11: Country Profile - Japan
  • Table 12: Country Profile - China
  • Table 13: Country Profile - India
  • Table 14: Leading Treatments for DES, 2015
  • Table 15: Product Profile - Restasis
  • Table 16: Restasis SWOT Analysis, 2015
  • Table 17: Global Sales Forecast ($m) for Restasis, 2014-2024
  • Table 18: Product Profile - Diquas
  • Table 19: Diquas SWOT Analysis, 2015
  • Table 20: Global Sales Forecast ($m) for Diquas, 2014-2024
  • Table 21: Product Profile - Mucosta
  • Table 22: Mucosta SWOT Analysis, 2015
  • Table 23: Global Sales Forecast ($m) for Mucosta, 2014-2024
  • Table 24: Product Profile - Ikervis
  • Table 25: Ikervis SWOT Analysis, 2015
  • Table 26: Global Sales Forecast ($m) for Ikervis, 2014-2024
  • Table 27: Artificial Tears SWOT Analysis, 2015
  • Table 28: Global Sales Forecast ($m) for Artificial Tears, 2014-2024
  • Table 29: Unmet Needs and Opportunities in DES
  • Table 30: Promising Drugs in Clinical Development for Dry Eye Syndrome, 2015
  • Table 31: Comparison of Drugs in Development for Dry Eye Syndrome, 2015
  • Table 32: Product Profile - Lifitegrast
  • Table 33: SWOT Analysis - Lifitegrast, 2015
  • Table 34: Global Sales Forecast ($m) for Lifitegrast, 2014-2024
  • Table 35: Product Profile - Tavilermide
  • Table 36: SWOT Analysis - tavilermide, 2015
  • Table 37: Global Sales Forecast ($m) for tavilermide, 2014-2024
  • Table 38: Product Profile - Visomitin
  • Table 39: SWOT Analysis - Visomitin, 2015
  • Table 40: Global Sales Forecast ($m) for Visomitin, 2014-2024
  • Table 41: Product Profile - RGN-259
  • Table 42: SWOT Analysis - RGN-259, 2015
  • Table 43: Global Sales Forecast ($m) for RGN-259, 2014-2024
  • Table 44: Product Profile - Cis-UCA
  • Table 45: Product Profile - SI-614
  • Table 46: Drugs in Development, 2015
  • Table 47: Key Companies in the Dry Eye Syndrome Market in the 9MM, 2014
  • Table 48: Allergan's DES Portfolio Assessment, 2015
  • Table 49: Herantis's DES Portfolio Assessment, 2015
  • Table 50: Mimetogen's DES Portfolio Assessment, 2015
  • Table 51: Mitotech's DES Portfolio Assessment, 2015
  • Table 52: Otsuka's DES Portfolio Assessment, 2015
  • Table 53: RegeneRx's DES Portfolio Assessment, 2015
  • Table 54: Santen's DES Portfolio Assessment, 2015
  • Table 55: Shire's DES Portfolio Assessment, 2015
  • Table 56: Global Sales Forecast ($m) for DES Therapies, 2014-2024
  • Table 57: DES Market - Drivers and Barriers, 2014-2024
  • Table 58: US Sales Forecast ($m) for DES Therapies, 2014-2024
  • Table 59: Key Events That Will Impact Sales for DES Therapies in the US, 2014-2024
  • Table 60: DES Market - Drivers and Barriers in the US, 2014-2024
  • Table 61: 5EU Sales Forecast ($m) for DES Therapies, 2014-2024
  • Table 62: Key Events Impacting Sales for DES Therapies in the 5EU, 2014-2024
  • Table 63: DES Market - Drivers and Barriers in the 5EU, 2014-2024
  • Table 64: National Healthcare Authorities and Governmental Drug Pricing Authorities in the 5EU Nations
  • Table 65: Japan Sales Forecast ($m) for DES Therapies, 2014-2024
  • Table 66: Key Events Impacting Sales for DES Therapies in Japan, 2014-2024
  • Table 67: DES Market - Drivers and Barriers in Japan, 2014-2024
  • Table 68: China Sales Forecast ($m) for DES Therapies, 2014-2024
  • Table 69: Key Events Impacting Sales for DES in China, 2014-2024
  • Table 70: DES Market - Drivers and Barriers in China, 2014-2024
  • Table 71: India Sales Forecast ($m) for DES, 2014-2024
  • Table 72: DES Market - Drivers and Barriers in India, 2014-2024
  • Table 73: Key Launch Dates
  • Table 74: Surveyed High-prescribing Physicians, by Country

List of Figures

  • Figure 1: Dry Eye Syndrome - Disease Etiology
  • Figure 2: The Tear Film in normal and dry eye
  • Figure 3: Varied Symptoms of Dry Eye Syndrome
  • Figure 4: 9MM, Total Prevalent Cases of Dry Eye Syndrome, Ages ≥20 Years, Men and Women, N, 2014-2024
  • Figure 5: 9MM, Total Prevalent Cases of Dry Eye Syndrome, by Age Group, N, 2014
  • Figure 6: 9MM, Total Prevalent Cases of Dry Eye Syndrome, by Sex, Ages ≥20 Years, N, 2014
  • Figure 7: 9MM, Age-Standardized Total Prevalence of Dry Eye Syndrome, Ages ≥20 Years, by Sex, 2014
  • Figure 8: Dry Eye Syndrome Therapeutics - Phase II and II/III Clinical Trials in the 9MM, 2015
  • Figure 9: DES Phase II/Phase III Pipeline, 2015
  • Figure 10: Competitive Assessment of Late-Stage Pipeline Agents in DES, 2014-2024
  • Figure 11: Clinical and Commercial Positioning of lifitegrast
  • Figure 12: Clinical and Commercial Positioning of tavilermide
  • Figure 13: Clinical and Commercial Positioning of Visomitin
  • Figure 14: Clinical and Commercial Positioning of RGN-259
  • Figure 15: Company Portfolio Gap Analysis in Dry Eye Syndrome, 2014-2024
  • Figure 16: Global Sales for DES Therapies by Region, 2014 and 2024
  • Figure 17: Global Sales by Region for DES Therapies, 2014-2024
  • Figure 18: Global Sales for DES by Drug, 2014 and 2024
  • Figure 19: Global Sales by Drug for DES Therapies, 2014-2024
  • Figure 20: Drug Sales for DES Therapies in the US, 2014 and 2024
  • Figure 21: Drug Sales for DES Therapies in the 5EU, 2014 and 2024
  • Figure 22: Drug Sales by country for DES in the 5EU, 2014 and 2024
  • Figure 23: Drug Sales for DES Therapies in Japan, 2014 and 2024
  • Figure 24: Drug Sales for DES Therapies in China, 2014 and 2024
  • Figure 25: Drug Sales for DES Therapies in India, 2014 and 2024
Back to Top